Reviva Pharmaceuticals (NASDAQ:RVPH) Shares Up 8.3% – Should You Buy?

Posted by Teresa Graham on Sep 26th, 2026

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) shot up 8.3% on Thursday. The company traded as high as $0.5279 and last traded at $0.52. 6,570 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 340,033 shares. The stock had previously closed at $0.48.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $53.33.

View Our Latest Analysis on Reviva Pharmaceuticals

Reviva Pharmaceuticals Trading Down 7.7%

The company has a market cap of $6.29 million, a PE ratio of -0.26 and a beta of 0.50. The company has a fifty day simple moving average of $0.49 and a two-hundred day simple moving average of $0.74.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19. On average, research analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 EPS for the current fiscal year.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.